Asia-Pacific Hospital-Acquired Infection Diagnostics Market By Product (Instrument and Reagents & Consumables) By Infection Type (Procedural Sedation, Pain Management, Emergency Medicine, Critical Care, General Floor, and Others), By Test Type (Molecular Diagnostics, Urinalysis, And Immunoassay) and End Use (Hospitals, Clinics and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027
- ALL4209120
- 228 Pages
- December 2020
- Medical Devices
Hospital-acquired infections (HAIs) are the infections caused by bacterial, viral, and fungal pathogens. These infections can be acquired in clinical settings, such as nursing home, rehabilitation facility, outpatient clinic, or other clinical settings. They can either be acquired from an infected patient, outside environment, or from the staff of that facility. The market is primarily driven by the increase in incidences of infections caused in clinical settings, especially in developing economies owing to their poor hygiene facilities.
The majority of HAI are caused by bacteria already present in the patient’s body prior to the infection, and may lead to cross-transmission between patients or between patients and healthcare professionals. The environment in a healthcare facility can also be a source of infection, with microorganism spread through air, water or surfaces. Patients in health facilities are more vulnerable than the general population due to underlying illness, greater fragility (such as for premature babies, the elderly, and immunocompromised patients), and exposure to invasive medical procedures. However, the increase in healthcare cost and prevalence of antibiotic resistant infections impedes the market growth.
Other factors contributing to infectious disease in hospitals include patients with contagious illnesses and patient exposure to infectious bodily fluids and other medical waste.
Furthermore, routine medical procedures, such as surgery, intubation and catheter placement, can allow infectious agents to enter the body. Hence, boost the Asia-Pacific hospital-acquired infection diagnostics market growth.
Country wise, the market is analyzed across India, Nepal, Bhutan, Bangladesh, Maldives, Sri Lanka, Myanmar, and Rest of Asia-Pacific. India accounted for the largest market share in 2019, and is expected to retain its dominance throughout the forecast period. This is attributed to the factors such as increase in prevalence of nosocomial infections, such as surgical site infections and blood stream infections. According to Indian Journal of Basic and Applied Medical Research, India reported an overall growth rate for hospital acquired infections of 4.4% after conducting a research on 10,835 patients in various clinical settings. Furthermore, Sri Lanka and Myanmar is anticipated to expand at a significant CAGR of 8.3% during the forecast period, owing to expeditiously improving healthcare systems and rise in healthcare expenditure and awareness regarding hospital-acquired infections.
The market is segmented on the basis of product, test type, infection type, end user, and country. By product, the market is bifurcated into instrument and reagents & consumables. By test type, the market is classified into molecular diagnostics, urinalysis, and immunoassay. By infection type, it is classified into hospital acquired pneumonia, bloodstream infections, surgical site infections, gastrointestinal Infections, urinary tract infections (UTI), and others.
The key players operating in the Asia-Pacific hospital-acquired infection diagnostics market include BECTON, DICKINSON AND COMPANY, Cepheid, Abbott Laboratories, F. Hoffmann-LA Roche Ltd, AstraZeneca, Daiichi Sankyo Co., Ltd., Hologic, Inc., Siemens, BIOMERIEUX SA, NG Biotech.
KEY BENEFITS FOR STAKEHOLDERS
• The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2019 to 2027, which is expected to enable stakeholders to capitalize on prevailing market opportunities.
• The key market players and their strategies have been analyzed to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
By Product type
• Instrument
• Consumables & Reagents
By Test Type
• Molecular Diagnostics
• Urinalysis
• Immunoassay
By Infection Type
• Hospital Acquired Pneumonia
• Bloodstream Infections
o Carbapenem Resistant Enterobacteriaceae
o Others
• Surgical Site Infections
o Methicillin Resistant Staphylococcus
o Others
• Gastrointestinal Infections
o Clostridium Difficile
o Others
• Urinary Tract Infections (UTI)
• Others
By End User
• Hospitals
• Clinics
• Others
By Country
• India
• Nepal
• Bhutan
• Bangladesh
• Maldives
• Sri Lanka
• Myanmar
• Rest of Asia Pacific
LIST OF KEY PLAYERS PROFILED IN THE REPORT
• Abbott Laboratories
• AstraZeneca
• BECTON, DICKINSON AND COMPANY
• BIOMERIEUX SA
• Cepheid
• Daiichi Sankyo Co., Ltd.
• F. Hoffmann-LA Roche Ltd.
• Hologic, Inc.
• NG Biotech
• Siemens
1.1.Report description
1.2.Key market segments
1.2.1.List of key players profiled in the report
1.3.Research methodology
1.3.1.Primary research
1.3.2.Secondary research
1.3.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Top winning strategies, 2019
3.3.Top player positioning
3.4.Top investment pockets
3.5.Key forces shaping capnography industry/market
3.6.Market dynamics
3.6.1.Drivers
3.6.1.1.Increase in geriatric population
3.6.1.2.HAIs and direct healthcare costs
3.6.1.3.Development of technologically advanced diagnostic products
3.6.1.4.Demand for hospital acquired infection diagnostics from middle and low-income countries
3.6.2.Restraints
3.6.2.1.Lack of awareness regarding hospital acquired infections
3.6.2.2.The consequences of antibiotic resistant infections
3.6.3.Opportunity
3.6.3.1.Introduction of awareness programs by various organizations
3.6.4.Impact Analysis
3.7.Impact analysis of COVID-19 on the Asia-Pacific hospital-acquired infection diagnostics market
3.7.1.Overview
3.7.2.Impact of COVID-19 on the market
CHAPTER 4:ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT
4.1.Overview
4.1.1.Market size and forecast, by product
4.2.Instrument
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast
4.2.3.Market analysis, by country
4.3.Reagents and consumables
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
CHAPTER 5:ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE
5.1.Overview
5.1.1.Market size and forecast, by test type
5.2.Molecular diagnostics
5.2.1.Market size and forecast
5.2.2.Market analysis, by country
5.3.Immunoassay
5.3.1.Market size and forecast
5.3.2.Market analysis, by country
5.4.Urinalysis
5.4.1.Market size and forecast
5.4.2.Market analysis, by country
CHAPTER 6:ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE
6.1.Overview
6.1.1.Market size and forecast, by Infection Type
6.2.Hospital acquired pneumonia
6.2.1.Market size and forecast, by country
6.2.2.Market analysis, by country
6.3.Bloodstream Infections
6.3.1.Market size and forecast, by country
6.3.2.Market analysis, by country
6.3.3.Bloodstream Infections, By type
6.3.3.1.Carbapenem Resistant Enterobacteriaceae
6.3.3.1.1.Market size and forecast, by infection type
6.3.3.1.2.Market size and forecast, by product
6.3.3.1.3.Market size and forecast, end user
6.3.3.1.4.Market size and forecast, by country
6.4.Surgical Site Infections
6.4.1.Market size and forecast, by country
6.4.2.Market analysis, by country
6.4.3.Surgical site infections, By type
6.4.3.1.Methicillin Resistant Staphylococcus
6.4.3.1.1.Market size and forecast, by infection type
6.4.3.1.2.Market size and forecast, by product
6.4.3.1.3.Market size and forecast, end user
6.4.3.1.4.Market size and forecast, by country
6.5.Gastrointestinal Infections
6.5.1.Market size and forecast, by country
6.5.2.Market analysis, by country
6.5.3.Gastrointestinal infections, By type
6.5.3.1.Clostridium Difficile
6.5.3.1.1.Market size and forecast, by infection type
6.5.3.1.2.Market size and forecast, by product
6.5.3.1.3.Market size and forecast, end user
6.5.3.1.4.Market size and forecast, by country
6.6.Urinary Tract Infections
6.6.1.Market size and forecast, by country
6.6.2.Market analysis, by country
6.7.Others
6.7.1.Market size and forecast, by country
6.7.2.Market analysis, by country
CHAPTER 7:ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER
7.1.Overview
7.1.1.Market size and forecast, end user
7.2.Hospitals
7.2.1.Market size and forecast, by country
7.2.2.Market analysis, by country
7.3.Clinics
7.3.1.Market size and forecast, by country
7.3.2.Market analysis, by country
7.4.Others
7.4.1.Market size and forecast, by country
7.4.2.Market analysis, by country
CHAPTER 8:ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY COUNTRY
8.1.Overview
8.1.1.Market size and forecast
8.2.India
8.2.1.Key market trends and growth opportunities
8.2.1.1.Market size and forecast, by product
8.2.1.2.Market size and forecast, test type
8.2.1.3.Market size and forecast, by Infection Type
8.2.1.4.Market size and forecast, end user
8.3.Nepal
8.3.1.Key market trends and growth opportunities
8.3.1.1.Market size and forecast, by product
8.3.1.2.Market size and forecast, test type
8.3.1.3.Market size and forecast, by Infection Type
8.3.1.4.Market size and forecast, end user
8.4.Bhutan
8.4.1.Key market trends and growth opportunities
8.4.1.1.Market size and forecast, by product
8.4.1.2.Market size and forecast, test type
8.4.1.3.Market size and forecast, by Infection Type
8.4.1.4.Market size and forecast, end user
8.5.Bangladesh
8.5.1.Key market trends and growth opportunities
8.5.1.1.Market size and forecast, by product
8.5.1.2.Market size and forecast, test type
8.5.1.3.Market size and forecast, by Infection Type
8.5.1.4.Market size and forecast, end user
8.6.Maldives
8.6.1.Key market trends and growth opportunities
8.6.1.1.Market size and forecast, by product
8.6.1.2.Market size and forecast, test type
8.6.1.3.Market size and forecast, by Infection Type
8.6.1.4.Market size and forecast, end user
8.7.Sri Lanka
8.7.1.Key market trends and growth opportunities
8.7.1.1.Market size and forecast, by product
8.7.1.2.Market size and forecast, test type
8.7.1.3.Market size and forecast, by Infection Type
8.7.1.4.Market size and forecast, end user
8.8.Myanmar
8.8.1.Key market trends and growth opportunities
8.8.1.1.Market size and forecast, by product
8.8.1.2.Market size and forecast, test type
8.8.1.3.Market size and forecast, by Infection Type
8.8.1.4.Market size and forecast, end user
8.9.Rest of Asia-Pacific
8.9.1.Key market trends and growth opportunities
8.9.1.1.Market size and forecast, by product
8.9.1.2.Market size and forecast, test type
8.9.1.3.Market size and forecast, by Infection Type
8.9.1.4.Market size and forecast, end user
CHAPTER 9:COMPANY PROFILES
9.1.ABBOTT LABORATORIES
9.1.1.Company overview
9.1.2.Company snapshot
9.1.3.Operating business segments
9.1.4.Product portfolio
9.1.5.Business performance
9.1.6.Key strategic moves and developments
9.2.ASTRAZENECA
9.2.1.Company overview
9.2.2.Company snapshot
9.2.3.Product portfolio
9.2.4.Business performance
9.3.BECTON, DICKINSON AND COMPANY
9.3.1.Company overview
9.3.2.Company snapshot
9.3.3.Operating business segments
9.3.4.Product portfolio
9.3.5.Business performance
9.4.BIOMERIEUX SA
9.4.1.Company overview
9.4.2.Company snapshot
9.4.3.Product portfolio
9.4.4.Business performance
9.5.CEPHEID
9.5.1.Company overview
9.5.2.Company snapshot
9.5.3.Operating business segments
9.5.4.Product portfolio
9.6.DAIICHI SANKYO CO., LTD.
9.6.1.Company overview
9.6.2.Company snapshot
9.6.3.Product Portfolio
9.6.4.Business performance
9.6.5.Key strategic moves and developments
9.7.F. HOFFMANN-LA ROCHE LTD.
9.7.1.Company overview
9.7.2.Company snapshot
9.7.3.Operating business segment
9.7.4.Product portfolio
9.7.5.Business performance
9.7.6.Key strategic moves and developments
9.8.HOLOGIC, INC.
9.8.1.Company overview
9.8.2.Company snapshot
9.8.3.Operating business segments
9.8.4.Product portfolio
9.8.5.Business performance
9.9.NG BIOTECH
9.9.1.Company overview
9.9.2.Company snapshot
9.9.3.Operating business segments
9.9.4.Product portfolio
9.9.5.Key strategic moves and developments
9.10.SIEMENS
9.10.1.Company overview
9.10.2.Company snapshot
9.10.3.Operating business segments
9.10.4.Product portfolio
9.10.5.Business performance
9.10.6.Key strategic moves and developments
TABLE 01.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 02.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR INSTRUMENT, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 03.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR REAGENTS AND CONSUMABLES, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 04.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 05.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 06.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR IMMUNOASSAY, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 07.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 08.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, 2019–2027 ($MILLION)
TABLE 09.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR HOSPITAL ACQUIRED PNEUMONIA, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 10.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR BLOODSTREAM INFECTIONS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 11.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR CARBAPENEM RESISTANT ENTEROBACTERIACEAE, BY INFECTION TYPE, 2019–2027 ($MILLION)
TABLE 12.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR CARBAPENEM RESISTANT ENTEROBACTERIACEAE, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 13.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR CARBAPENEM RESISTANT ENTEROBACTERIACEAE, BY END USER, 2019–2027 ($MILLION)
TABLE 14.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR CARBAPENEM RESISTANT ENTEROBACTERIACEAE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 15.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR SURGICAL SITE INFECTIONS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 16.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR METHICILLIN RESISTANT STAPHYLOCOCCUS, BY INFECTION TYPE, 2019–2027 ($MILLION)
TABLE 17.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR METHICILLIN RESISTANT STAPHYLOCOCCUS, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 18.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR METHICILLIN RESISTANT STAPHYLOCOCCUS, BY END USER, 2019–2027 ($MILLION)
TABLE 19.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR METHICILLIN RESISTANT STAPHYLOCOCCUS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 20.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR GASTROINTESTINAL INFECTIONS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 21.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE, BY INFECTION TYPE, 2019–2027 ($MILLION)
TABLE 22.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 23.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE, BY END USER, 2019–2027 ($MILLION)
TABLE 24.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 25.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR URINARY TRACT INFECTIONS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 26.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 27.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 28.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 29.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR CLINICS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 30.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 31.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 32.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR INDIA, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 33.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR INDIA, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 34.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR INDIA, BY INFECTION TYPE, 2019–2027 ($MILLION)
TABLE 35.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR INDIA, BY END USER, 2019–2027 ($MILLION)
TABLE 36.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR NEPAL, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 37.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR NEPAL, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 38.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR NEPAL, BY INFECTION TYPE, 2019–2027 ($MILLION)
TABLE 39.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR NEPAL, BY END USER, 2019–2027 ($MILLION)
TABLE 40.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR BHUTAN, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 41.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR BHUTAN, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 42.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR BHUTAN, BY INFECTION TYPE, 2019–2027 ($MILLION)
TABLE 43.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR BHUTAN, BY END USER, 2019–2027 ($MILLION)
TABLE 44.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR BANGLADESH, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 45.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR BANGLADESH, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 46.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR BANGLADESH, BY INFECTION TYPE, 2019–2027 ($MILLION)
TABLE 47.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR BANGLADESH, BY END USER, 2019–2027 ($MILLION)
TABLE 48.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR MALDIVES, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 49.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR MALDIVES, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 50.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR MALDIVES BY INFECTION TYPE, 2019–2027 ($MILLION)
TABLE 51.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR MALDIVES, BY END USER, 2019–2027 ($MILLION)
TABLE 52.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR SRI LANKA, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 53.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR SRI LANKA, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 54.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR SRI LANKA, BY INFECTION TYPE, 2019–2027 ($MILLION)
TABLE 55.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR SRI LANKA, BY END USER, 2019–2027 ($MILLION)
TABLE 56.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR MYANMAR, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 57.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR MYANMAR, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 58.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR MYANMAR, BY INFECTION TYPE, 2019–2027 ($MILLION)
TABLE 59.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR MYANMAR, BY END USER, 2019–2027 ($MILLION)
TABLE 60.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR REST OF ASIA-PACIFIC, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 61.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR REST OF ASIA-PACIFIC, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 62.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR REST OF ASIA-PACIFIC, BY INFECTION TYPE, 2019–2027 ($MILLION)
TABLE 63.ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET FOR REST OF ASIA-PACIFIC, BY END USER, 2019–2027 ($MILLION)
TABLE 64.ABBOTT: COMPANY SNAPSHOT
TABLE 65.ABBOTT: OERATING SEGMENT
TABLE 66.ABBOTT: PRODUCT PORTFOLIO
TABLE 67.ABBOTT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 68.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 69.ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 70.BD: SNAPSHOT
TABLE 71.BD: OPERATING SEGMENTS
TABLE 72.BD: PRODUCT PORTFOLIO
TABLE 73.BIOMERIEUX: COMPANY SNAPSHOT
TABLE 74.BIOMERIEUX: PRODUCT PORTFOLIO
TABLE 75.CEPHEID: COMPANY SNAPSHOT
TABLE 76.CEPHEID: OPERATING BUSINESS SEGMENTS
TABLE 77.CEPHEID: PRODUCT PORTFOLIO
TABLE 78.DAIICHI SANKYO: COMPANY SNAPSHOT
TABLE 79.DAIICHI SANKYO: PRODUCT PORTFOLIO
TABLE 80.ROCHE: COMPANY SNAPSHOT
TABLE 81.ROCHE: OPERATING SEGMENT
TABLE 82.ROCHE: PRODUCT PORTFOLIO
TABLE 83.HOLOGIC: COMPANY SNAPSHOT
TABLE 84.HOLOGIC: OPERATING BUSINESS SEGMENTS
TABLE 85.HOLOGIC: PRODUCT PORTFOLIO
TABLE 86.NG BIOTECH: COMPANY SNAPSHOT
TABLE 87.NG BIOTECH: OPERATING SEGMENTS
TABLE 88.NG BIOTECH: PRODUCT PORTFOLIO:
TABLE 89.SIEMENS: COMPANY SNAPSHOT
TABLE 90.SIEMENS: OPERATING SEGMENTS
TABLE 91.SIEMENS: PRODUCT PORTFOLIO
Similar Reports
Medical implants are permanent devices such as pacemakers or temporary devices such as fracture plates which are removed once their function is completed. These implants are made up of bone, tissue, skin, ceramics, metals, plastics, and other natural materials...
- Publish Date: August 21, 2016
- $5370
Ostomy is a surgery wherein an artificial opening, known as stoma, is created from the colon in the human body to eliminate body wastes such as urine, mucus, and stools, which are collected in artificial bags called ostomy drainage bags. These plastic/rub...
- Publish Date: December 1, 2016
- $5370
Laparoscopy is a minimally invasive procedure used to examine organs inside the abdomen or pelvic cavities by inserting a laparoscope through a small incision in the abdomen. A laparoscope comprises a long, thin tube with high-intensity light, and high-re...
- Publish Date: April 24, 2017
- $5370
